On that note, I emailed Resverlogix IR last week pointing out that their ClinicalTrials.gov listing hasn't been updated for 14 months and includes several outdated pieces of info (dosing period, recruitment status, estimated completion date). I also pointed out the ambiguity in the stated duration of the safety follow up period (4 to 16 weeks) as listed in company presentations and posters. I asked for a clarification since this may infuence when last patient visit and data set lock occurs, which may in turn affect timing of final adjudication and top-line data release. The response I received was "Clinicaltrials.gov will be updated in early 2019 with relevant amendments."